The company behind Wegovy has officially launched a new oral weight loss pill, marking a major shift in how prescription weight management treatments are delivered — and who can access them.
The tablet form of Wegovy was approved by the U.S. Food and Drug Administration on December 22, 2025, and became broadly available in U.S. pharmacies on January 5, 2026. The pill is now offered through several online platforms, including Amazon Pharmacy and Weight Watchers, allowing patients to obtain treatment without injections.
Pricing varies depending on coverage. With insurance, some patients may pay as little as $25 per month, while cash-paying options reportedly begin around $149 per month, according to Amazon. The expanded access is expected to appeal to patients who previously faced cost, convenience, or delivery barriers.
Until now, Wegovy had only been available as a once-weekly self-injection, first approved for weight management in 2021. The new oral version offers a daily pill alternative for patients who prefer tablets over injections and is reported to have a similar efficacy profile to the injectable form.
Health experts caution that prescription weight loss medications are not intended as quick fixes. Proper medical screening, ongoing supervision, and lifestyle changes remain essential components of safe and effective treatment. As access expands through digital platforms, questions around long-term use, affordability, and responsible prescribing are likely to remain in focus.
The launch also underscores a broader shift toward digital-first healthcare, as major retailers and wellness brands play a growing role in prescription delivery. With demand for medical weight management continuing to rise, the oral option may significantly widen adoption — while reshaping how patients engage with care.
